DelveInsight's,“ Cholestatic Pruritus Pipeline Insights 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Cholestatic Pruritus pipeline landscape. It covers the Cholestatic Pruritus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholestatic Pruritus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cholestatic Pruritus Pipeline? Click here to explore the therapies and trials making headlines @ Cholestatic Pruritus Pipeline Outlook Report

Key Takeaways from the Cholestatic Pruritus Pipeline Report

• On 09 October 2025, Mirum Pharmaceuticals Inc. announced a clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
• DelveInsight's Cholestatic Pruritus Pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Cholestatic Pruritus treatment.
• The leading Cholestatic Pruritus Companies such as Escient Pharmaceuticals, Cara Therapeutics, GlaxoSmithKline, CymaBay Therapeutics, Mirum Pharmaceuticals and others.
• Promising Cholestatic Pruritus Therapies such as EP547, Linerixibat, Maralixibat, LUM001, A4250, and others.

Want to know which companies are leading innovation in Cholestatic Pruritus? Dive into the full pipeline insights @ Cholestatic Pruritus Clinical Trials Assessment

Cholestatic Pruritus Overview

Cholestasis is defined as impaired secretion of bile. Pruritus is a complication of cholestasis including that associated with mutations in genes that code for transporters in the hepatocyte and from inflammatory liver diseases. Pruritus is a debilitating symptom reported among 80% to 100% of patients with cholestatic liver disease, including primary biliary cholangitis, primary sclerosing cholangitis, and intrahepatic cholestasis of pregnancy. Cholestatic pruritus is severe.

Cholestatic Pruritus Emerging Drugs Profile

• Volixibat: Mirum Pharmaceuticals

Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the apical sodium dependent bile acid transporter (ASBT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of ASBT, thereby reducing bile acids systemically and in the liver. Phase 1 and Phase 2 studies of volixibat demonstrated on-target fecal bile acid excretion, a pharmacodynamic marker of ASBT inhibition, in addition to decreases in LDL cholesterol and increases in 7αC4 which are markers of bile acid synthesis. Volixibat has been evaluated in more than 400 individuals across multiple clinical trials. The most common adverse events reported were mild to moderate gastrointestinal events observed in the volixibat groups. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cholestatic Pruritus.

• Linerixibat: GlaxoSmithKline

Linerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC and it is not currently approved for use anywhere in the world. In 2019, FDA granted orphan drug designation for linerixibat in the treatment of PBC and associated cholestatic pruritus. Linerixibat is a minimally absorbed small molecule inhibitor of IBAT administered as an oral tablet. By blocking resorption of bile acids in the small intestine, linerixibat reduces pruritic bile acids in circulation. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Cholestatic Pruritus.

If you're tracking ongoing Cholestatic Pruritus Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Cholestatic Pruritus Treatment Drugs

Cholestatic Pruritus Companies

Escient Pharmaceuticals, Cara Therapeutics, GlaxoSmithKline, CymaBay Therapeutics, Mirum Pharmaceuticals and others.

The Cholestatic Pruritus Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Cholestatic Pruritus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cholestatic Pruritus Treatment.
• Cholestatic Pruritus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cholestatic Pruritus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cholestatic Pruritus Market.

Cholestatic Pruritus Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Cholestatic Pruritus Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Cholestatic Pruritus Pipeline Report covers it all – check it out now @ Cholestatic Pruritus Market Drivers and Barriers, and Future Perspectives

Scope of the Cholestatic Pruritus Pipeline Report

• Coverage- Global
• Cholestatic Pruritus Companies- Escient Pharmaceuticals, Cara Therapeutics, GlaxoSmithKline, CymaBay Therapeutics, Mirum Pharmaceuticals, and others.
• Cholestatic Pruritus Therapies- EP547, Linerixibat, Maralixibat, LUM001, A4250, and others.
• Cholestatic Pruritus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cholestatic Pruritus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Cholestatic Pruritus Treatment landscape in this detailed analysis @ Cholestatic Pruritus Emerging Drugs and Major Players

Table of Contents